Friday, 20 November 2026European Markets

NYKODE THERAPEUTIC Stock Impressive Jump Before The Weekend, Outperforms Market

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - The Market ended the session with NYKODE THERAPEUTIC (NYKD.OL) rising 10.72% to kr5.00 on Friday, following the last session's downward trend. Oslo Børs Benchmark Index_GI rose 0.93% to kr1,449.45, following the last session's downward trend on what was a somewhat up trend exchanging session today.

NYKODE THERAPEUTIC's last close was kr4.52, 81.42% under its 52-week high of kr24.30.

About NYKODE THERAPEUTIC

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, NYKODE THERAPEUTIC has a trailing twelve months EPS of kr-1.26.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -25.99%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 88.5%, now sitting on 6.52M for the twelve trailing months.

Volatility

NYKODE THERAPEUTIC's last week, last month's, and last quarter's current intraday variation average was a negative 0.50%, a negative 1.34%, and a positive 5.07%.

NYKODE THERAPEUTIC's highest amplitude of average volatility was 2.44% (last week), 4.10% (last month), and 5.07% (last quarter).

Sales Growth

NYKODE THERAPEUTIC's sales growth is negative 27% for the current quarter and 102.2% for the next.

More news about NYKODE THERAPEUTIC (NYKD.OL).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 4 Oct 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›